Online ISSN: 1949-2553
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

Drug Discovery in Academia; Dumping in the Publication Landfill?

News

February 5, 2024
PRESS RELEASE: On January 24, 2024, a new editorial was published in Oncotarget, entitled, “The fate of drug discovery in academia; dumping in the publication landfill?” continue reading »

BCAS1 Defines a Heterogeneous Cell Population in Diffuse Glioma Patients

News

January 31, 2024
PRESS RELEASE: On January 24, 2024, a new research paper was published in Oncotarget, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.” continue reading »

Genetic Alterations in Thyroid Cancer Mediate Resistance to BRAF Inhibition and Anaplastic Transformation

News

January 29, 2024
PRESS RELEASE: On January 24, 2024, a new research perspective was published in Oncotarget, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.” continue reading »

Case Report: Lazarus Effect in a Patient Treated With Osimertinib for NSCLC With Leptomeningeal Disease

News

January 24, 2024
PRESS RELEASE: On January 16, 2024, a new case report was published in Oncotarget, entitled, “Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.” continue reading »